Purchase this article with an account.
Y. Rotenstreich, A. Solomon, A. Skaat, I. Moroz; Increased Scotopic and Photopic A-Wave Amplitude Electroretinogram Responses After Intravitreal Bevacizumab Injection in Patients With Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1885.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the effect of Bevacizumab (Avastin®), a vascular endothelial growth factor inhibitor on the retinal function by full-field electroretinogram (ERG) in patients with choroidal neovascular Age-related Macular Degeneration (AMD).
Masked, controlled study, included 12 patients with choroidal neovascular AMD, mean age 72 ± 11.5 years, (5 men and 7 women) . The patients were injected with bevacizumab 1.25 mg/0.05 ml (Genentech, San Francisco, CA) unilaterally into the vitreous cavity as part of the standard management. Prior to bevacizumab injection and one month post-injection, full-field ERG (ISCEV; LKC Technologies, Gaithersburg, MD) scans were obtained from both eyes of each patient while the other eye was used as a control group. Scotopic responses were recorded under four incremental light intensities stimuli (0.099 cd-s/m2, 2.44 cd-s/m2, 23.5 cd-s/m2 and 252 cd-s/m2). The photopic responses were evoked by two incremental light intensities (2.44 cd-s/m2 and 7.8 cd-s/m2). The differences before and after treatment for the waves amplitude were calculated and the data were analyzed using repeated measure ANOVA model.
The average differences for the incremental light intestacies of the scotopic a-wave amplitude in the injected eyes was 15.92 microvolt, compare to 1.33 microvolt in the controlled eyes (P=0.057, ANOVA). The average differences of the photopic a-wave amplitude were 4.97 microvolt in the injected eye and -1.06 microvolt in the control eyes (P=0.01, ANOVA). The average differences of the scotopic b-wave amplitude in the injected and controlled eyes were 13.56 microvolt and 4.11 microvolt respectively (P=0.23, ANOVA). The average differences for the photopic b-wave amplitude in the injected eyes was 5.07 microvolt and -2.70 microvolt in the controlled eyes (P=0.048, ANOVA).
Intravitreal injection of bevacizumab improved rods and cones function in neovascular AMD patients. No significant measurable photoreceptor toxicity was observed by the ERG tests.
Clinical Trial: :
This PDF is available to Subscribers Only